Chardan Capital Reaffirms “Buy” Rating for Arbutus Biopharma (ABUS)

Chardan Capital reissued their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS) in a research report report published on Tuesday, January 16th.

Several other equities analysts also recently commented on the company. Zacks Investment Research downgraded Arbutus Biopharma from a hold rating to a sell rating in a research report on Thursday, January 18th. B. Riley assumed coverage on Arbutus Biopharma in a report on Friday, January 5th. They issued a buy rating and a $10.00 target price for the company. BidaskClub upgraded Arbutus Biopharma from a sell rating to a hold rating in a report on Thursday, January 4th. ValuEngine cut Arbutus Biopharma from a sell rating to a strong sell rating in a report on Friday, December 15th. Finally, Leerink Swann reiterated a market perform rating and issued a $5.00 target price (up from $4.00) on shares of Arbutus Biopharma in a report on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Arbutus Biopharma currently has an average rating of Hold and an average target price of $12.50.

Arbutus Biopharma (ABUS) traded up $0.05 during midday trading on Tuesday, hitting $5.30. The stock had a trading volume of 433,524 shares, compared to its average volume of 182,520. The company has a market cap of $291.78, a P/E ratio of -1.06 and a beta of 1.12. The company has a current ratio of 11.03, a quick ratio of 11.03 and a debt-to-equity ratio of 0.08. Arbutus Biopharma has a 52-week low of $2.50 and a 52-week high of $8.25.

Institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new stake in Arbutus Biopharma in the fourth quarter valued at about $146,000. Vanguard Group Inc. increased its holdings in shares of Arbutus Biopharma by 2.7% in the second quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 2,035 shares during the period. OxFORD Asset Management LLP increased its holdings in shares of Arbutus Biopharma by 89.9% in the second quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares during the period. Victory Capital Management Inc. increased its holdings in shares of Arbutus Biopharma by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 150,720 shares of the biopharmaceutical company’s stock valued at $761,000 after purchasing an additional 21,460 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in shares of Arbutus Biopharma in the third quarter valued at about $1,393,000. Institutional investors own 60.00% of the company’s stock.

WARNING: This news story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://ledgergazette.com/2018/02/12/arbutus-biopharma-abus-rating-reiterated-by-chardan-capital.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply